Serum levels of tumor necrosis factor-alpha, soluble intercellular adhesion molecule-1, soluble vascular cell adhesion molecule-1, and soluble interleukin-1 receptor antagonist in patients with thyroid eye disease undergoing treatment with somatosta

scientific article

Serum levels of tumor necrosis factor-alpha, soluble intercellular adhesion molecule-1, soluble vascular cell adhesion molecule-1, and soluble interleukin-1 receptor antagonist in patients with thyroid eye disease undergoing treatment with somatosta is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1089/10507250152740957
P698PubMed publication ID12186498

P2093author name stringA E Heufelder
G E Krassas
N Pontikides
D Doukidis
G Heufelder
P433issue12
P921main subjectcell adhesionQ187640
interleukinsQ194908
eye diseaseQ3041498
P304page(s)1115-1122
P577publication date2001-12-01
P1433published inThyroidQ15709940
P1476titleSerum levels of tumor necrosis factor-alpha, soluble intercellular adhesion molecule-1, soluble vascular cell adhesion molecule-1, and soluble interleukin-1 receptor antagonist in patients with thyroid eye disease undergoing treatment with somatosta
P478volume11

Reverse relations

cites work (P2860)
Q36675481Cortistatin as a therapeutic target in inflammation.
Q35600019Opportunities in somatostatin research: biological, chemical and therapeutic aspects
Q36595134Pharmacological treatments for thyroid eye disease.
Q35785161Somatostatin analogs: a new tool for the management of Graves' ophthalmopathy
Q33999578Somatostatin negatively regulates parasite burden and granulomatous responses in cysticercosis
Q81024281The effect of etanercept on Graves' ophthalmopathy: a pilot study

Search more.